South and Central America Hypertrophic and Keloid Scar Treatment Market Growth by 2027

The hypertrophic and keloid scar treatment market in South and Central America is expected to grow from US$ 248.42 million in 2020 to US$ 477.69 million by 2027; it is estimated to grow at a CAGR of 9.8% from 2020 to 2027.

Brazil and Argentina are major economies in South and Central America. Emerging treatments modalities is the major factor driving the growth of the South and Central America hypertrophic and keloid scar treatment market. At present, there are various treatments available to treat hypertrophic and keloid scars. The emerging treatments are based on stem cell therapy, verapamil, mitomycin C (MMC), interferons, bleomycin, ACE inhibitors, and botulinum toxin type A. Most of these treatments have shown promising results. On the other hand, the topical products are being used to reduce the thickness of scars and lighten them as they are esthetically unpleasing. However, laser treatment and radiotherapy are associated with side effects, and they do not heal the scars completely. Therefore, researchers are continuously studying these treatments and are yet to derive a standard treatment for hypertrophic and keloid scars. Likewise, manufacturers are also engaged in developing products such as extracellular-matrix that control the proliferation of collagen, thereby preventing the excess deposition of the same. Keloid scars can also be related to genetic factors; hence, they are considered major clinical challenges. Therefore, the ongoing research and developments are likely to provide preventive measures and extraordinary treatments for hypertrophic and keloid scars treatment during the forecast period, which is further anticipated to drive the market in South and Central America.

South and Central America has witnessed a growing number of cases of COVID-19 since its outbreak. For example, according to the Worldometer, the number of cases reached 13,382,026, with 366,256 recorded deaths in South America as of January 2021. In Brazil, the first case of COVID-19 was confirmed on February 26, 2020, and now, the cases have reached 7,754,560, with 196,591 deaths. Argentina and Colombia reached 1,648,940 and 1,686,131 cases of COVID-19 as of January 2021. COVID-19 is predicted to result in the region's worst recession, causing the region's GDP to contract by 9.1% in 2020. This is projected to increase the number of poor by 45 million and the highly poor by 28 million. The COVID‐19 pandemic is a vital test for the still overburdened and underfunded public health systems of South and Central America. Moreover, it will decrease imports due to disruptions in global trade, further increasing the scarcity of medical supplies and other goods, resulting in a significant price increase.

South and Central America Hypertrophic and Keloid Scar Treatment Market Segmentation

South and Central America Hypertrophic and Keloid Scar Treatment Market – By Scar Type

• Hypertrophic
• Keloid

South and Central America Hypertrophic and Keloid Scar Treatment Market – By Product Type

• Injectables
• Topical
  • Gels
  • Silicone Sheets
  • Creams
  • Other
• Laser
  • CO2
  • Pulse-Dyed
  • Other
• Other

South and Central America Hypertrophic and Keloid Scar Treatment Market – By End User

• Hospitals
• Clinics
• Homecare

South and Central America Hypertrophic and Keloid Scar Treatment Market, by Country

• Brazil
• Argentina
• Rest of South & Central America

South and Central America Hypertrophic and Keloid Scar Treatment Market-Companies Mentioned

• Alliance Pharma PLC
• HRA Pharma
• Mölnlycke Health Care AB.
• Newmedical Technology Inc.
• Perrigo Company plc
• Smith & Nephew
• Sonoma Pharmaceuticals, Inc
• Suneva Medical

South and Central America Hypertrophic and Keloid Scar Treatment Report Scope